This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Plans to double its manufacturing footprint to bolster the growth
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
The combined company will be able to better serve both our global and regional customers with local production
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Subscribe To Our Newsletter & Stay Updated
